Showing results (411-420 of 427) with videos related to
Sort By:
Pageof 43
Annals of Hematology|July 8, 2025
VINCENT: A randomized-controlled trial evaluating venetoclax plus azacitidine versus intensive chemotherapy in patients with newly diagnosed, NPM1-mutated AMLLydia Kretschmer, Leo Ruhnke, Christoph Schliemann, et al.Blood|July 28, 2021
CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcomeFranziska Taube, Julia Annabell Georgi, Michael Kramer, et al.Blood|June 5, 2020
Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?Christoph Röllig, Michael Kramer, Christoph Schliemann, et al.Journal of Hematology & Oncology|May 13, 2022
Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestationsJan-Niklas Eckardt, Friedrich Stölzel, Desiree Kunadt, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 16, 2024
Single or Double Induction With 7 + 3 Containing Standard or High-Dose Daunorubicin for Newly Diagnosed AML: The Randomized DaunoDouble Trial by the Study Alliance LeukemiaChristoph Röllig, Björn Steffen, Christoph Schliemann, et al.Journal of Hematology & Oncology|September 5, 2022
Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantationDesiree Kunadt, Sebastian Stasik, Klaus H Metzeler, et al.American Journal of Hematology|January 6, 2026
Randomized Comparison of Cardiotoxicity With 60 Versus 90 mg Daunorubicin in AML Induction TherapyStefan Markus Dendorfer, Katharina Schmidt-Brücken, Michael Kramer, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 21, 2019
Chromosomal Abnormalities and Prognosis in <i>NPM1</i>-Mutated Acute Myeloid Leukemia: A Pooled Analysis of Individual Patient Data From Nine International CohortsLinus Angenendt, Christoph Röllig, Pau Montesinos, et al.Blood Advances|November 18, 2021
Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter studyJan M Middeke, Klaus H Metzeler, Christoph Röllig, et al.Blood Cancer Journal|October 5, 2021
Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemiaChristina Rautenberg, Friedrich Stölzel, Christoph Röllig, et al.Pageof 43